for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Beigene And Springworks Announce Presentation Of Preclinical Data From Solid Tumors Treatment

June 22 (Reuters) - Springworks Therapeutics Inc:

* BEIGENE AND SPRINGWORKS ANNOUNCE PRESENTATION OF PRECLINICAL DATA COMBINING RAF DIMER INHIBITOR LIFIRAFENIB WITH MEK INHIBITOR MIRDAMETINIB AND PROVIDE UPDATE ON ONGOING PHASE 1B/2 CLINICAL TRIAL

* SPRINGWORKS THERAPEUTICS - ONGOING PHASE 1B/2 CLINICAL TRIAL ON TRACK TO COMMENCE DOSE EXPANSION COHORTS IN KRAS MUTANT SOLID TUMORS BY 2020-END Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up